Brief: Impact Biomedical Says On July 21 Entered Debt Conversion Agreement With DSS
28/07/2025 16:13
July 28 (Reuters) - Impact Biomedical Inc IBO.A: IMPACT BIOMEDICAL INC - ON JULY 21, ENTERS DEBT CONVERSION AGREEMENT WITH DSS - SEC FILING IMPACT BIOMEDICAL INC - TO ISSUE 31,939,778 SHARES TO SETTLE DEBT - SEC FILING Source text: [ID:n0001641172-25-021085] Further company coverage: IBO.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Impact Biomedical
See all newsBrief: Impact BioMedical Announces 1 For 12.62 Reverse Stock Split To Pursue Completion Of Merger With Zoar
Brief: Impact Biomedical Says On July 21 Entered Debt Conversion Agreement With DSS
Brief: Dr Ashleys Limited And Impact Biomedical Inc. Announce Strategic Merger
Brief: Impact BioMedical Announces Issuance Of Canadian Patent For Linebacker Technology Targeting Inflammatory Disease
Brief: Impact Biomedical Inc. Announces Pricing Of Initial Public Offering